Interleukin-2 plus ribavirin versus interferon-α-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-α-2b treatment

BioDrugs

Volumn 18, Issue 6, 2004, Pages 407-413

  Malaguarnera, Mariano ^a   Pistone, Giovanni ^a   Neri, Sergio ^a   Romano, Marcello ^b   Brogna, Alfio ^a   Musumeci, Salvatore ^c,d  

^a UNIVERSITY OF CATANIA   (Italy)

^b GARIBALDI HOSPITAL   (Italy)

^c UNIVERSITY OF SASSARI   (Italy)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2; RIBAVIRIN; VIRUS RNA;

ADULT; ANOREXIA; ANTIVIRAL ACTIVITY; ANXIETY; ARTICLE; BONE PAIN; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; EDEMA; ERYTHEMA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; IRRITABILITY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MYALGIA; NAUSEA; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETREATMENT; WEIGHT REDUCTION;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; INTERLEUKIN-2; LIVER; LIVER FUNCTION TESTS; MALE; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; TREATMENT FAILURE;

EID: 11144323777     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200418060-00006     Document Type: Article

References (25)

1. Gish RG. Standards of treatment in chronic hepatitis C. Semin Liver Dis 1999; 19: 35-47
2. Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995; 15: 82-91
3. Fried MW. Therapy of chronic viral hepatitis. Med Clin North Am 1996; 80: 957-72
4. Malaguarnera M, Restuccia S, Trovato G, et al. Interferon alpha treatment in patients with chronic hepatitis C: a meta-analytic evaluation. Clin Drug Invest 1995; 9: 141-9
5. McHutchinson JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92
6. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32
7. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa 2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-9
8. Manns MP, McHutchison TG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65
9. Bach N, Schaffner F, Lin SC. High dose recombinant interleukin-2 for chronic viral hepatitis [letter]. Lancet 1989; II (8657): 281
10. Paul W, Sederer RA. Lymphocyte response and cytokines. Cell 1994; 76: 241-51
11. Sher A, Coffmann RL. Regulation of immunity to parasites by T cells and T cell derived cytokines. Annu Rev Immunol 1992; 10: 385-409
12. Kakumu S, Fuji A, Yoshioka K, et al. Pilot study of recombinant human interleukin-2 for chronic type B hepatitis. Hepatology 1988; 8: 487-92
13. Pardo M, Castillo I, Oliva H, et al. A pilot study of recombinant interleukin 2 for treatment of chronic hepatitis C. 1997; 26: 1318-21
14. Stuyver L, Rossan R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1983; 74: 1093-102
15. Simmonds P, Alberti P, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-4
16. Knodell RG, Ishack KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1991; 1: 431-5
17. Ishack K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9
18. Cohen J. Statistical power analysis for the behavioural sciences. Hillsdale (NJ): Lawrence Erlabaum Associates, 1988: 12-18
19. Cummings KJ, Lee SM, West ES, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomised trials. JAMA 2001; 285: 193-9
20. Farci P, Shinoda A, Coiana A, et al. The outcome of acute hepatitis C predicted by evolution of the viral quasispecies. Science 2000; 288: 339-4
21. Cerny A, Chisari FV. Pathogenesis of chronic hepatitis C: immunological features of hepatic injury and viral persistence. Hepatology 1999; 30: 595-601
22. Onji M, Kondoh H, Norhke N, et al. Effect of recombinant interleukin-2 on hepatitis B e antigen positive chronic hepatitis. Gut 1987; 28: 1648-52
23. Ramsay AJ, Ruby J, Ramshaw IA. A case for cytokines as effector molecules in the resolution of virus infection. Immunol Today 1993; 14: 155-7
24. Bertoletti A, D'Elios MN, Boni C, et al. Different cytokine profiles of intrahepatic T-cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology 1997; 112: 193-9
25. Oldham RK. In vivo effects of IL-2. J Biol Response Mod 1984; 9: 455-532